PMID- 29775310
OWN - NLM
STAT- Publisher
LR  - 20180518
IS  - 1520-4804 (Electronic)
IS  - 0022-2623 (Linking)
DP  - 2018 May 18
TI  - Fragment-based discovery of a potent, orally bioavailable inhibitor which
      modulates the phosphorylation and catalytic activity of ERK1/2.
LID - 10.1021/acs.jmedchem.8b00421 [doi]
AB  - Aberrant activation of the MAPK pathway drives cell proliferation in multiple
      cancers. Inhibitors of BRAF and MEK kinases are approved for the treatment of
      BRAF mutant melanoma, but resistance frequently emerges, often mediated by
      increased signalling through ERK1/2. Here we describe the fragment based
      generation of ERK1/2 inhibitors which block catalytic phosphorylation of
      downstream substrates such as RSK but also modulate phosphorylation of ERK1/2 by 
      MEK without directly inhibiting MEK. X-ray crystallographic and biophysical
      fragment screening followed by structure-guided optimization and growth from the 
      hinge into a pocket proximal to the C-alpha helix afforded highly potent ERK1/2
      inhibitors with excellent kinome selectivity. In BRAF mutant cells the lead
      compound suppresses pRSK and pERK levels and inhibits proliferation at low
      nanomolar concentrations. The lead exhibits tumor regression upon oral dosing in 
      BRAF mutant xenograft models, providing a promising basis for further
      optimization towards clinical pERK1/2 modulating ERK1/2 inhibitors.
FAU - Heightman, Tom D
AU  - Heightman TD
FAU - Berdini, Valerio
AU  - Berdini V
FAU - Braithwaite, Hannah
AU  - Braithwaite H
FAU - Buck, Ildiko Maria
AU  - Buck IM
FAU - Cassidy, Megan
AU  - Cassidy M
FAU - Castro, Juan
AU  - Castro J
FAU - Courtin, Aurelie
AU  - Courtin A
FAU - Day, James E H
AU  - Day JEH
FAU - East, Charlotte
AU  - East C
FAU - Fazal, Lynsey
AU  - Fazal L
FAU - Graham, Brent
AU  - Graham B
FAU - Griffiths-Jones, Charlotte M
AU  - Griffiths-Jones CM
FAU - Lyons, John F
AU  - Lyons JF
FAU - Martins, Vanessa
AU  - Martins V
FAU - Muench, Sandra
AU  - Muench S
FAU - Munck, Joanne M
AU  - Munck JM
FAU - Norton, David
AU  - Norton D
FAU - O'Reilly, Marc
AU  - O'Reilly M
FAU - Palmer, Nick
AU  - Palmer N
FAU - Pathuri, Puja
AU  - Pathuri P
FAU - Reader, Michael
AU  - Reader M
FAU - Rees, David C
AU  - Rees DC
FAU - Rich, Sharna J
AU  - Rich SJ
FAU - Richardson, Caroline
AU  - Richardson C
FAU - Saini, Harpreet
AU  - Saini H
FAU - Thompson, Neil T
AU  - Thompson NT
FAU - Wallis, Nicola G
AU  - Wallis NG
FAU - Walton, Hugh
AU  - Walton H
FAU - Wilsher, Nicola E
AU  - Wilsher NE
FAU - Woolford, Alison J-A
AU  - Woolford AJ
FAU - Cooke, Michael
AU  - Cooke M
FAU - Cousin, David
AU  - Cousin D
FAU - Onions, Stuart
AU  - Onions S
FAU - Shannon, Jonathan
AU  - Shannon J
FAU - Watts, John
AU  - Watts J
FAU - Murray, Christopher W
AU  - Murray CW
LA  - eng
PT  - Journal Article
DEP - 20180518
PL  - United States
TA  - J Med Chem
JT  - Journal of medicinal chemistry
JID - 9716531
EDAT- 2018/05/19 06:00
MHDA- 2018/05/19 06:00
CRDT- 2018/05/19 06:00
PHST- 2018/05/19 06:00 [entrez]
PHST- 2018/05/19 06:00 [pubmed]
PHST- 2018/05/19 06:00 [medline]
AID - 10.1021/acs.jmedchem.8b00421 [doi]
PST - aheadofprint
SO  - J Med Chem. 2018 May 18. doi: 10.1021/acs.jmedchem.8b00421.